Cardiology, Renal and Metabolic (CaReMe) group have produced a very helpful leaflet for people with diabetes on SGLT-2 inhibitors.
SGLT-2 inhibitors are being increasingly used in people with type 2 diabetes to improve diabetes control with the added benefits of weight loss, reduction in BP, reduction in admission from heart failure, reduction in cardiovascular and overall mortality and reduction in renal deterioration.
The leaflet will help improve patient care with the optimal use of SGLT-2 inhibitors and provide very important and relevant information to the people who use this group of drug.
It can be sent by e-mail, shared through website or the leaflet can be printed, folded and given to people with diabetes attending any clinic.
